TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)
Brief Summary: This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis


Options:
A: Arm Label: Group 1 (Guselkumab: Placebo); Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Arm Label: Group 2 (Placebo: Guselkumab); Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Group 1 (Guselkumab: Placebo), Group 2 (Placebo: Guselkumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1 (Guselkumab: Placebo), Group 2 (Placebo: Guselkumab)
B: Arm Label: Adalimumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo for risankizumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Biological: placebo for adalimumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: BIOLOGICAL; Name: placebo for adalimumab; Assigned to Arm(s): Risankizumab (Part A)
C: Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab 45/90 mg, Drug: placebo secukinumab | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg | Intervention Type: DRUG; Name: ustekinumab 45/90 mg; Assigned to Arm(s): Ustekinumab | Intervention Type: DRUG; Name: placebo secukinumab; Assigned to Arm(s): Ustekinumab
D: Arm Label: Group I: Guselkumab Plus Placebo; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Arm Label: Group II: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Group I: Guselkumab Plus Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I: Guselkumab Plus Placebo | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Group II: Secukinumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)
Brief Summary: This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis


Options:
A: Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab 45/90 mg, Drug: placebo secukinumab | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg | Intervention Type: DRUG; Name: ustekinumab 45/90 mg; Assigned to Arm(s): Ustekinumab | Intervention Type: DRUG; Name: placebo secukinumab; Assigned to Arm(s): Ustekinumab
B: Arm Label: M1095 (Sonelokimab) 30mg; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 60mg; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 120mg - regimen 1; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 120mg - regimen 2; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: Placebo / M1095 (Sonelokimab) 120mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: M1095 (Sonelokimab), Drug: Placebo | Arm Label: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Intervention Type: DRUG; Name: M1095 (Sonelokimab); Assigned to Arm(s): M1095 (Sonelokimab) 120mg - regimen 1, M1095 (Sonelokimab) 120mg - regimen 2, M1095 (Sonelokimab) 30mg, M1095 (Sonelokimab) 60mg, Placebo / M1095 (Sonelokimab) 120mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / M1095 (Sonelokimab) 120mg | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab
C: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Guselkumab; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Guselkumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Guselkumab
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) to Reduce Oral Corticosteroid Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy (ZONDA)
Brief Summary: The purpose of this trial is to confirm if benralizumab can reduce the use of maintenance OCS in systemic corticosteroid dependent patients with severe refractory asthma with elevated eosinophils.


Options:
A: Arm Label: Benralizumab Arm A; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab Arm B; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm A | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm B
B: Arm Label: CAT-354 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 1mg/kg | Arm Label: CAT-354 5 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 5 mg/kg | Arm Label: CAT-354 10mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 10mg/kg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: CAT-354 1mg/kg; Assigned to Arm(s): CAT-354 1 mg/kg | Intervention Type: BIOLOGICAL; Name: CAT-354 5 mg/kg; Assigned to Arm(s): CAT-354 5 mg/kg | Intervention Type: BIOLOGICAL; Name: CAT-354 10mg/kg; Assigned to Arm(s): CAT-354 10mg/kg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: OAT + Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Other: Optimized asthma therapy | Arm Label: Optimized Asthma Treatment (OAT); Type: ACTIVE_COMPARATOR; Interventions: Other: Optimized asthma therapy | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): OAT + Omalizumab | Intervention Type: OTHER; Name: Optimized asthma therapy; Assigned to Arm(s): OAT + Omalizumab, Optimized Asthma Treatment (OAT)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Consistency, Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 50 Years of Age or Older
Brief Summary: The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.


Options:
A: Arm Label: HZ/su Lot A; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine (GSK 1437173A) | Arm Label: HZ/su Lot B; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine (GSK 1437173A) | Arm Label: HZ/su Lot C; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine (GSK 1437173A) | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine (GSK 1437173A); Assigned to Arm(s): HZ/su Lot A, HZ/su Lot B, HZ/su Lot C
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: Varicella-zoster vaccine | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Varicella-zoster vaccine; Assigned to Arm(s): Arm 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Arm 2
C: Arm Label: GSK1437173A 18-30 Years Old Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling for assay of persistence of immunogenicity | Arm Label: GSK1437173A 50-70 Years Old Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling for assay of persistence of immunogenicity | Intervention Type: PROCEDURE; Name: Blood sampling for assay of persistence of immunogenicity; Assigned to Arm(s): GSK1437173A 18-30 Years Old Group, GSK1437173A 50-70 Years Old Group
D: Arm Label: NBP608; Type: EXPERIMENTAL; Interventions: Biological: NBP608 | Arm Label: Zostavax; Type: ACTIVE_COMPARATOR; Interventions: Biological: Zostavax | Intervention Type: BIOLOGICAL; Name: NBP608; Assigned to Arm(s): NBP608 | Intervention Type: BIOLOGICAL; Name: Zostavax; Assigned to Arm(s): Zostavax

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Consistency, Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 50 Years of Age or Older
Brief Summary: The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.


Options:
A: Arm Label: Co-Ad Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK 1437173A; Assigned to Arm(s): Co-Ad Group, Control Group | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A; Assigned to Arm(s): Co-Ad Group, Control Group
B: Arm Label: GSK1437173A group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster Vaccine GSK1437173A | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Herpes Zoster Vaccine GSK1437173A; Assigned to Arm(s): GSK1437173A group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo group
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: Varicella-zoster vaccine | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Varicella-zoster vaccine; Assigned to Arm(s): Arm 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Arm 2
D: Arm Label: HZ/su Lot A; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine (GSK 1437173A) | Arm Label: HZ/su Lot B; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine (GSK 1437173A) | Arm Label: HZ/su Lot C; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine (GSK 1437173A) | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine (GSK 1437173A); Assigned to Arm(s): HZ/su Lot A, HZ/su Lot B, HZ/su Lot C

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Protein and Resistance Training on Muscle Mass, Muscle Strength and Functional Ability in Acutely Ill Old Medical Patients; a Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine the effect of a high-protein diet during hospitalization in combination with resistance training and a daily protein and energy supplement three months after discharge on the muscle mass, muscle strength, functional ability and weight in acutely ill old medical patients.


Options:
A: Arm Label: Intensive physical therapy; Type: EXPERIMENTAL; Interventions: Procedure: intensive physical therapy | Arm Label: control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: control group | Intervention Type: PROCEDURE; Name: intensive physical therapy; Assigned to Arm(s): Intensive physical therapy | Intervention Type: PROCEDURE; Name: control group; Assigned to Arm(s): control group
B: Arm Label: Intervention exercise; Type: EXPERIMENTAL; Interventions: Other: Intervention exercise | Arm Label: Sham exercise; Type: SHAM_COMPARATOR; Interventions: Other: Sham Exercise | Intervention Type: OTHER; Name: Intervention exercise; Assigned to Arm(s): Intervention exercise | Intervention Type: OTHER; Name: Sham Exercise; Assigned to Arm(s): Sham exercise
C: Arm Label: Strength training; Type: EXPERIMENTAL; Interventions: Other: Strength training | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Strength training; Assigned to Arm(s): Strength training
D: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: High-protein diet and resistance training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: High-protein diet and resistance training; Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Exercise Training in Prevention and Treatment of Diastolic Heart Failure- Clinical Study
Brief Summary: Aim of the clinical multicenter study (OptimEx-CLIN) is to assess the optimal exercise intervention in patients with Heart Failure with preserved Ejection Fraction (HFpEF; also termed diastolic heart failure) that will best improve peak oxygen uptake (Peak Vo2) and additionally diastolic function (assessed echocardiographically). The investigators hypothesize that exercise training reverses HFpEF and that intensity of exercise training is more important than duration.


Options:
A: Arm Label: Exercise Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Dietary Intervention; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Dietary Intervention | Arm Label: Attention control; Type: ACTIVE_COMPARATOR; Interventions: Other: Attention Control | Arm Label: Diet and Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise, Behavioral: Diet and exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Diet and Exercise, Exercise Training | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Intervention; Assigned to Arm(s): Dietary Intervention | Intervention Type: BEHAVIORAL; Name: Diet and exercise; Assigned to Arm(s): Diet and Exercise | Intervention Type: OTHER; Name: Attention Control; Assigned to Arm(s): Attention control
B: Arm Label: Tai Chi; Type: EXPERIMENTAL; Interventions: Behavioral: 12-week Tai Chi Program | Arm Label: Heart Health Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 12-week Education Program | Intervention Type: BEHAVIORAL; Name: 12-week Tai Chi Program; Assigned to Arm(s): Tai Chi | Intervention Type: BEHAVIORAL; Name: 12-week Education Program; Assigned to Arm(s): Heart Health Education
C: Arm Label: High Intensity Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: High Intensity Exercise | Arm Label: Moderate Continuous Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Moderate Continuous Exercise | Arm Label: Usual Care; Type: SHAM_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: High Intensity Exercise; Assigned to Arm(s): High Intensity Exercise | Intervention Type: BEHAVIORAL; Name: Moderate Continuous Exercise; Assigned to Arm(s): Moderate Continuous Exercise | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Walking intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Walking intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Walking intervention; Assigned to Arm(s): Walking intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Virtual Reality Based Training - a Motivating and Effective Way of Regaining Arm Motor Function After Stroke? The VIRTUES Trial: A Multi-center RCT
Brief Summary: Background: High intensity training of challenging tasks with many repetitions is a key factor for regaining motor function after stroke. Novel virtual reality (VR) rehabilitation systems provide the potential to increase intensity and offer challenging and motivating tasks. The efficacy of VR systems has not been demonstrated yet in sufficiently powered studies.

Methods: In 5 participating rehabilitation centers patients in the subacute phase after stroke will be randomized to either a group receiving 4 weeks of VR training in addition to conventional arm training or a group receiving dose-matched and therapist attention-matched conventional arm-training.

Hypothesis: VR training is more effective in improving arm motor function than conventional arm training in the subacute phase after stroke.


Options:
A: Arm Label: VRT; Type: EXPERIMENTAL; Interventions: Other: virtual reality training | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: control | Intervention Type: OTHER; Name: virtual reality training; Assigned to Arm(s): VRT | Intervention Type: OTHER; Name: control; Assigned to Arm(s): control
B: Arm Label: Nintendo Wii FitTM; Type: EXPERIMENTAL; Interventions: Other: Wii Fit | Arm Label: Lower extremity exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Lower Extremity Exercise | Intervention Type: OTHER; Name: Wii Fit; Assigned to Arm(s): Nintendo Wii FitTM | Intervention Type: OTHER; Name: Lower Extremity Exercise; Assigned to Arm(s): Lower extremity exercise
C: Arm Label: Virtual reality; Type: EXPERIMENTAL; Interventions: Device: Virtual Reality | Arm Label: Conventional arm training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional arm training | Intervention Type: DEVICE; Name: Virtual Reality; Assigned to Arm(s): Virtual reality | Intervention Type: BEHAVIORAL; Name: Conventional arm training; Assigned to Arm(s): Conventional arm training
D: Arm Label: E-glove system; Type: EXPERIMENTAL; Interventions: Device: E-glove system | Arm Label: Conventional occupational therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional occupational therapy | Intervention Type: DEVICE; Name: E-glove system; Assigned to Arm(s): E-glove system | Intervention Type: PROCEDURE; Name: Conventional occupational therapy; Assigned to Arm(s): Conventional occupational therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section
Brief Summary: Postpartum hemorrhage (PPH) is a common complication of childbirth and a leading cause of maternal morbidity and mortality. The prompt and effective treatment of subjects with PPH would reduce operation risks. Hence in this study, the efficacy of Oxytocin and Carbetocin was compared in prevention of postpartum hemorrhage after cesarean sections.


Options:
A: Arm Label: Carbetocin 20mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 40mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 60mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 80mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 20mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 40mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 60mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 80mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 100mcg
B: Arm Label: tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: transamin | Arm Label: saline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: transamin; Assigned to Arm(s): tranexamic acid
C: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Carbetocin; Type: EXPERIMENTAL; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
D: Arm Label: Carbetocin; Type: N/A; Interventions: N/A | Arm Label: Oxytocin; Type: N/A; Interventions: N/A

Answer: C